PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀’s New Drug Application
Watch PolyPid's latest callPolyPid (NASDAQ:PYPD) Q2 2026 Earnings Call · Replay · Aug 12Read the transcript of PolyPid (NASDAQ:PYPD) Q2 2026 Earnings CallPolyPid's next earnings callPolyPid (NASDAQ:PYPD) Q3 2026 Earnings Call · Nov 11, 2026 at 8:30 AM ESTRegister
The original release is unavailable here.
Earlier from PolyPid
- PolyPid Announces Participation in Upcoming Investor Conferences
- PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
- PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026
- PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors
- PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission
Later from PolyPid
- PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA
- PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026
- PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting
- PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026
- PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results
Follow PolyPid into a list and get an email when it puts out news.
Follow PolyPid